PGR and triple-negative breast carcinoma: Four molecular phenotypes (luminal A, luminal B, HER2+, and triple-negative breast cancer (TNBC)) are characterized by the presence of estrogen (ER+) and progesterone receptors (PR+), as well as human epidermal growth factor receptor 2 (HER2+/neu) [4].